Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.
| dc.contributor.author | Blanco Ares, Gonzalo, 1989- | ca |
| dc.contributor.author | Puiggros Metje, Anna Maria | ca |
| dc.contributor.author | Rodríguez-Rivera, María | ca |
| dc.contributor.author | Gimeno Vázquez, Eva | ca |
| dc.contributor.author | Abella Monreal, Eugenia | ca |
| dc.contributor.author | Ferrer Del Alamo, Ana | ca |
| dc.contributor.author | Espinet Solà, Blanca | ca |
| dc.date.accessioned | 2017-02-08T12:41:57Z | |
| dc.date.available | 2017-02-08T12:41:57Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | Patients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (TP53abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable clinical outcome. Chromosome 8 abnormalities, namely losses of 8p (8p-) and gains of 8q (8q+) have been suggested to aggravate the outcome of patients with TP53abs. However, the reported series were small, thus hindering definitive conclusions. To gain insight into this issue, we assessed a series of 101 CLL patients harboring TP53 disruption. The frequency of 8p- and 8q+ was 14.7% and 17.8% respectively. Both were associated with a significantly (P < 0.05) higher incidence of a complex karyotype (CK, ≥3 abnormalities) detected by chromosome banding analysis (CBA) compared to cases with normal 8p (N-8p) and 8q (N-8q), respectively. In univariate analysis for 10-year overall survival (OS), 8p- (P = 0.002), 8q+ (P = 0.012) and CK (P = 0.009) were associated with shorter OS. However, in multivariate analysis only CK (HR = 2.47, P = 0.027) maintained independent significance, being associated with a dismal outcome regardless of chromosome 8 abnormalities. In conclusion, our results highlight the association of chromosome 8 abnormalities with CK amongst CLL patients with TP53abs, while also revealing that CK can further aggravate the prognosis of this aggressive subgroup. | ca |
| dc.description.sponsorship | This work has been supported by the following grants: PI11/01621, PI15/00437, RD09/0076/00036,RD12/0036/0044, RD12/0036/0069 and PT13/0010/0005 FEDER, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness; 2014/SGR585 from Generalitat de Catalunya; “Xarxa de Bancs de tumors” sponsored by Pla Director d’Oncologia de Catalunya (XBTC) and Fundació La Caixa; the Swedish Cancer Society, the Swedish Research Council, the Lion’s Cancer Research Foundation, and Selander’s Foundation, Uppsala; H2020 “AEGLE, An analytics framework for/nintegrated and personalized healthcare services in Europe” by the EU. | |
| dc.format.mimetype | application/pdf | ca |
| dc.identifier.citation | Blanco G, Puiggros A, Baliakas P, Athanasiadou A, García-Malo M, Collado R. et al. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget. 2016 Dec 6;7(49):80916-80924. doi: 10.18632/oncotarget.13106 | ca |
| dc.identifier.doi | http://dx.doi.org/10.18632/oncotarget.13106 | |
| dc.identifier.issn | 1949-2553 | |
| dc.identifier.uri | http://hdl.handle.net/10230/28084 | |
| dc.language.iso | eng | ca |
| dc.publisher | Impact Journals | ca |
| dc.relation.ispartof | Oncotarget. 2016 Dec 6;7(49):80916-24 | |
| dc.rights | All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License. | ca |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca |
| dc.rights.uri | https://creativecommons.org/licenses/by/3.0/ | ca |
| dc.subject.other | Leucèmia aguda -- Aspectes genètics | ca |
| dc.subject.other | Leucèmia limfocítica | ca |
| dc.title | Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. | ca |
| dc.type | info:eu-repo/semantics/article | ca |
| dc.type.version | info:eu-repo/semantics/publishedVersion | ca |
Files
Original bundle
1 - 1 of 1

